Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 7;104(6):e41415.
doi: 10.1097/MD.0000000000041415.

Advances in controlled release drug delivery systems based on nanomaterials in lung cancer therapy: A review

Jiang Fu  1   2 , Li Yu  3 , Zixu Wang  1   2 , Haoyu Chen  1 , Song Zhang  1 , Haining Zhou  1   2   4
Affiliations
Review

Advances in controlled release drug delivery systems based on nanomaterials in lung cancer therapy: A review

Jiang Fu et al. Medicine (Baltimore). .

Abstract

Lung cancer is one of the most common malignant tumors, with the highest morbidity and mortality rates. Currently, significant progress has been made in the treatment of lung cancer, which has effectively improved the overall prognosis of patients, but there are still many problems, such as tumor recurrence, drug resistance, and serious complications. With the rapid development of nanotechnology in the field of medicine, it breaks through the inherent limitations of traditional cancer treatments and shows great potential in tumor treatment. To address the drawbacks of traditional therapeutic means, nanodrug delivery systems can release drugs under specific conditions, thus realizing tumor-targeted drug delivery, which improves the antitumor effect of drugs. In this paper, we review the current treatments for lung cancer and further discuss the advantages and common carriers of nanodrug delivery systems. We also summarize the latest research progress of nanotargeted drug delivery systems in the field of lung cancer therapy, discuss the problems faced in their clinical translation, and look forward to future development opportunities and directions.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
The current primary treatment modalities for lung cancer. PD-1 = programmed cell death receptor 1, PD-L1 = programmed cell death ligand 1.
Figure 2.
Figure 2.
Classification of carriers for nanodrug delivery systems.
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. - PubMed
    1. Guo X, Zhuang Q, Ji T, et al. Multi-functionalized chitosan nanoparticles for enhanced chemotherapy in lung cancer. Carbohydr Polym. 2018;195:311–20. - PubMed
    1. Zhou B, Zang R, Song P, et al. Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study. J Transl Med. 2023;21:10. - PMC - PubMed
    1. Chan MH, Huang WT, Wang J, Liu RS, Hsiao M. Next-generation cancer-specific hybrid theranostic nanomaterials: MAGE-A3 NIR persistent luminescence nanoparticles conjugated to afatinib for in situ suppression of lung adenocarcinoma growth and metastasis. Adv Sci (Weinh). 2020;7:1903741. - PMC - PubMed
    1. Huang W, Yan Y, Liu Y, et al. Exosomes with low miR-34c-3p expression promote invasion and migration of non-small cell lung cancer by upregulating integrin α2β1. Signal Transduct Target Ther. 2020;5:39. - PMC - PubMed

MeSH terms

Substances